Mays Cancer Center researcher and SignalRx earn NCI business grants to develop drugs for first-in-human clinical trials
An internationally recognized physician-scientist of Mays Cancer Center at UT Health San Antonio, together with SignalRx Pharmaceuticals Inc., have secured two National Cancer Institute business grants to further develop drugs on a pathway to first-in-human cancer clinical trials. The clinical translational researcher, Daruka Mahadevan, MD, PhD, division chief of hematology and medical oncology at UT […]